PASG Insider Trading

Insider Ownership Percentage: 4.30%
Insider Buying (Last 12 Months): $408,099.13
Insider Selling (Last 12 Months): $516,689.42

Passage Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Passage Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$29ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Passage Bio Share Price & Price History

Current Price: $0.33
Price Change: Price Increase of +0.001 (0.30%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for PASG up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$0.33Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Passage Bio (NASDAQ:PASG)

53.48% of Passage Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PASG by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$382kbought$814ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal InflowsTotal Outflows
Passage Bio logo
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Read More on Passage Bio

Today's Range

Now: $0.33
Low: $0.31
High: $0.36

50 Day Range

MA: $0.44
Low: $0.33
High: $0.56

52 Week Range

Now: $0.33
Low: $0.30
High: $1.64

Volume

157,546 shs

Average Volume

331,513 shs

Market Capitalization

$20.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Who are the company insiders with the largest holdings of Passage Bio?

Passage Bio's top insider shareholders include:
  1. Lynx1 Capital Management Lp (Major Shareholder)
  2. Orbimed Advisors Llc (Major Shareholder)
  3. Mark S Forman (Insider)
  4. Alexandros Fotopoulos (Insider)
  5. Kathleen Borthwick (CFO)
  6. Simona King (CFO)
Learn More about top insider investors at Passage Bio.